

Supplementary Table 1. Clinical and tumor characteristics between different age groups of patients with GGOs in total cohort

Characteristics	Total cohort						P value
	Total, No. (%)	Age, years, No. (%)					
		<40	40-49	50-59	60-69	≥70	
Median age (years, range)	55.0 (17.0-90.0)	36.0 (17.0-39.0)	45.0 (40.0-49.0)	54.0 (50.0-59.0)	64.0 (60.0-69.0)	74.0 (70.0-90.0)	<0.001
Gender							0.002
Male	498 (33.8)	53 (32.5)	94 (28.4)	127 (30.7)	140 (37.6)	84 (43.5)	
Female	975 (66.2)	110 (67.5)	237 (71.6)	287 (69.3)	232 (63.4)	109 (56.5)	
Smoking history							0.003
No	1300 (88.3)	150 (92.0)	306 (92.4)	363 (87.7)	311 (83.6)	170 (88.1)	
Yes	173 (11.7)	13 (8.0)	25 (7.6)	51 (12.3)	61 (16.4)	23 (11.9)	
Tumor diameter							<0.001
≤2cm	1312 (89.1)	160 (98.2)	315 (95.2)	372 (89.9)	318 (85.5)	147 (76.2)	
>2cm	161 (10.9)	3 (1.8)	16 (4.8)	42 (10.1)	54 (14.5)	46 (23.8)	
GGO type							<0.001
Pure	750 (50.9)	113 (69.3)	202 (61.0)	226 (54.6)	146 (39.2)	63 (32.6)	
Mixed							
CTR ≤0.5	334 (22.7)	34 (20.9)	83 (25.1)	101 (24.4)	79 (21.3)	37 (19.2)	
CTR >0.5	389 (26.4)	16 (9.8)	46 (13.9)	87 (21.0)	147 (39.5)	93 (48.2)	
Pathological type							<0.001
AAH or AIS	264 (17.9)	39 (23.9)	82 (24.8)	76 (18.4)	49 (13.2)	18 (9.3)	
MIA	396 (26.9)	73 (44.8)	118 (35.6)	108 (26.1)	66 (17.7)	31 (16.1)	
IAC	813 (55.2)	51 (31.3)	131 (39.6)	230 (55.5)	257 (69.1)	144 (74.6)	
Pathologic stage							<0.001
AAH/AIS	264 (17.9)	39 (23.9)	82 (24.8)	76 (18.4)	49 (13.2)	18 (9.3)	
IA1	607 (41.2)	102 (62.6)	166 (50.2)	181 (43.7)	105 (28.2)	53 (27.5)	
IA2	448 (30.4)	19 (11.7)	68 (20.5)	116 (28.0)	166 (44.6)	79 (40.9)	
IA3	137 (9.3)	2 (1.2)	12 (3.6)	39 (9.4)	46 (12.4)	38 (19.7)	
IB	17 (1.2)	1 (0.6)	3 (0.9)	2 (0.5)	6 (1.6)	5 (2.6)	
EGFR status							<0.001
Negative	378 (25.7)	47 (28.8)	96 (29.0)	87 (21.0)	103 (27.7)	45 (23.3)	
Postive	507 (34.4)	30 (18.4)	75 (22.7)	156 (37.7)	166 (44.6)	80 (41.5)	
NA	588 (39.9)	86 (52.8)	160 (48.3)	171 (41.3)	103 (27.7)	68 (35.2)	

AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; CTR, consolidation-to-tumor ratio; EGFR, epidermal growth factor receptor; GGO, ground-glass opacities; IAC, invasive adenocarcinoma cancer; MIA, minimally invasive adenocarcinoma; NA, not available; No., number.